Ifinatamab is a humanised monoclonal immunoglobulin that targets and inhibits the B7-H3 protein. Ifinatamab can be used to synthesise the ADC drug Ifinatamab deruxtecan for the treatment of small cell lung cancer (SCLC).
Purity:
95.00%
CAS Number:
[2484870-90-6]
Target:
Immunology/Inflammation related|||Integrin|||B7
* VAT and and shipping costs not included. Errors and price changes excepted